Canalys:次季全球平板電腦出貨量大增26%至3,754萬台
調查機構Canalys發表的報告指,次季全球平板電腦出貨量按年大增26.1%至3,754.2萬台,認為期內需求主要受惠客戶及企業正尋找可負擔的基本設備,以及較大屏幕以助遙距工作、學習及娛樂。報告指期內廠商有效提升產能應對需求,而同時零售商及電訊商亦有為客戶提供優惠或數據等以鼓勵消費者購買。
按品牌劃分,蘋果次季平板電腦出貨量達1,424.9萬台,按年增長19.8%,市佔率達38%居首位,排名第二的三星出貨量則按年大增39.2%至702.4萬台,而華為出貨量則按年急升44.5%至477萬台,Lenovo出貨量亦按年大升52.9%至281萬台,市佔7.5%排名第五。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.